Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy (ROBO-GYN)

March 12, 2026 updated by: Centre Oscar Lambret

Assessment of Perioperative Morbidity in Gyneco-oncology According to the Surgical Approach : Coelioscopy Versus Robot-assisted Coelioscopy

The purpose of this study is to compare perioperative morbidity of coelioscopy versus robot-assisted coelioscopy in cervical cancer, uterus cancer and ovarian cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Laparoscopic surgery, also called minimally invasive surgery (MIS), is a surgical method less invasive than classical laparoscopic open procedure. Particularly, MIS is used for resection of some gynecological cancer such as endometrial cancer, cervical cancer or ovarian cancer. Several studies demonstrated that MIS induce less surgical complications (bleeding, infections, post-operative pains...), shorter hospitalization time, earlier recovery of activity and better quality of life than laparoscopic open procedure.

However, MIS is the selected method in only 9 to 25 % of gynecologic cancer surgery in France. This is likely due to the longer learning curve of MIS compared to laparoscopic open procedure.

In 2001 the FDA allowed the use of robot assisted laparoscopic surgery (RALS). This technique adds some advantage to laparoscopic surgery. Indeed, surgeon operates with better precision while seated comfortably at a computer console viewing a 3-D image of the surgical field. Moreover learning curve of RALS is shorter than MIS. Comparative studies between RALS and MIS demonstrate an equivalence of these techniques for operation length and bleeding. However for surgery linked complications and time for recovery of activity, RALS had better results than MIS.

Despite its expensive cost, RALS is now commonly used in North America (90% of prostatectomy and 40% of cancer linked hysterectomy). However RALS need to be evaluated in a randomized clinical trial before it's acceptation in gyneco-oncology in France.

Thus, the purpose of the ROBOGYN clinical trial is to compare clinical benefit of RALS and MIS in a randomized study for patients with cancer of cervix, uterus or ovary.

Study Type

Interventional

Enrollment (Actual)

386

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Bordeaux, France, 33300
        • CHU Bordeaux, Hôpital Saint-André
      • Bordeaux, France, 33300
        • Polyclinique Bordeaux Nord Aquitaine
      • Lille, France, 59000
        • Centre Oscar Lambret
      • Lille, France, 59037
        • CHRU Lille, Hôpital Jeanne de Flandres
      • Limoges, France, 87042
        • CHU Limoges
      • Marseille, France, 13009
        • Institut Paoli Calmette
      • Nîmes, France, 30029
        • CHU Nimes
      • Nîmes, France, 30900
        • Polyclinique Kenval
      • Paris, France, 75015
        • Hôpital Européen Georges Pompidou
      • Reims, France, 51100
        • Polyclinique Courlancy
      • Roubaix, France, 59056
        • Centre Hospitalier de Roubaix
      • Saint-Herblain, France, 44805
        • Institut de cancerologie de l'ouest site Rene Gauducheau
      • Toulouse, France, 31052
        • Institut Claudius Regaud
      • Toulouse, France, 31059
        • CHU Rangueil
      • Tours, France, 37044
        • CHRU de Tours
      • Valenciennes, France, 59322
        • Centre Hospitalier de Valenciennes
      • Vandœuvre-lès-Nancy, France, 54511
        • Centre Alexis Vautrin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • patient with uterus cancer depending on hysterectomy ± pelvic lymphadenectomy or a restadification
  • patient with cervical cancer depending on enlarged colpo-hysterectomy ± pelvic lymphadenectomy or a surgery after concomitant radiochemotherapy, or lombo aortic lymphadenectomy for a locally advanced cancer, or a restadification
  • patient with cervical cancer depending on a restadification
  • patient aged over 18 years
  • previous antitumor treatment allowed but necessarily disrupted 20 days before inclusion
  • WHO score equal or inferior to 3
  • cirrhosis-related Child-Pugh score under or equal to A7 are allowed
  • life expectancy equal or superior to 12 weeks
  • patient affiliated to health insurance
  • dated and signed informed consent

Exclusion Criteria:

  • metastatic disease
  • pregnant or breastfeeding woman
  • patient unable to proceed follow-up visit, because of geographic, social or mental reasons

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard Coelioscopy
gynecologic surgery - standard coelioscopy
Procedure: gynecologic surgery - standard coelioscopy
lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
Experimental: Robot-assisted coelioscopy
gynecologic surgery - robot assisted coelioscopy
Procedure: gynecologic surgery - robot assisted coelioscopy
lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perioperative morbidity at six months
Time Frame: six months after surgery
To estimate the rate of complications within the first six months after surgery, according to the Clavien-Dindo and NCI CTCAE-v4.0 grading scales
six months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anesthesic and ventilator parameters
Time Frame: every 30 min during the surgery
Description of anesthesic and ventilator parameters
every 30 min during the surgery
Post-operative analgesia
Time Frame: at 24h, 48h after sugery and until discharge
collect of antalgic treatments
at 24h, 48h after sugery and until discharge
Surgeon's ergonomy
Time Frame: every hour during surgery (Borg scale), and at the end of intervention (NASA-TLX scale)
according to Borg and NASA-TLX scales
every hour during surgery (Borg scale), and at the end of intervention (NASA-TLX scale)
Patient-reported survey of patient health
Time Frame: until 2 years after surgery
36-item short form health Survey (SF36) : Scoring is a two-step process. First, numeric values of all items are recoded per the scoring key (for example, values are 0/100, or 0/25/50/75/100 depending the items). All items are scored so that a high score defines a more favorable health state. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores: physical functioning, Role functioning/physical, Role functioning/emotional, Energy/fatigue, Emotional well-being, Social functioning, Pain, General health, Health change. Scale scores represent the average for all items in the scale that the respondent answered.
until 2 years after surgery
Description of surgical procedures
Time Frame: during surgery
operative time (overall intervention, incision or "skin-to-skin", robot).
during surgery
Progression-free survival
Time Frame: until 2 years after surgery
delay between the date of randomization and the date of the following event: local relapse, regional relapse, metastasis or death.
until 2 years after surgery
Anatomopathology
Time Frame: during surgery
rate of exeresis with histologically healthy resection margins (R0), number of lymph nodes removed.
during surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Oscar Lambret

Collaborators

National Cancer Institute, France
CRG : Groupe Francophone de Chirurgie Robotique en Gynécologie

Investigators

  • Principal Investigator: Fabrice NARDUCCI, MD, Centre Oscar Lambret, Lille
  • Study Director: Eric LAMBAUDIE, MD, Institut Paoli-Calmettes

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2010

Primary Completion (Actual)

March 1, 2016

Study Completion (Actual)

November 1, 2017

Study Registration Dates

First Submitted

November 19, 2010

First Submitted That Met QC Criteria

November 23, 2010

First Posted (Estimated)

November 24, 2010

Study Record Updates

Last Update Posted (Actual)

March 13, 2026

Last Update Submitted That Met QC Criteria

March 12, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ROBOGYN - 1004
  • 2010-A00605-34 (Other Identifier: ANSM)
  • PHRC10-1908 (Other Grant/Funding Number: DGOS/INCA)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe